Czech/SlovakiaCzech RepublicSlovakia

New Instrument Gives Tax Breaks for R&D in the Czech Republic

10.12.2004

Prague - At the beginning of November the Czech Government has passed a new income tax law providing tax benefits for research and development (R&D) in the Czech Republic. The Chamber of Deputies voted 'Yes' on the modified bill which introduces a deductible item of 100% of costs allocated for R&D. The bill now has to be affirmed by the senate. The new legislation will then come into force on January 1, 2005. The essence of the support resides in the fact that R&D costs, which can be regularly declared for tax purposes and included in every company's costs, will now be eligible to be deducted once more at 100% from the calculated tax base. The deductible item is thus seen as an effective tax instrument to support R&D. “It will provide major support to companies operating in the Czech Republic and will contribute to a higher competitiveness of our country,” commented Martin Jahn, Deputy Prime Minister for Economic Affairs.
The introduction of new tax breaks for R&D aims at increasing the attractiveness of the Czech Republic as a country suitable for such R&D activities. The approval should help after the phase of foreign investors' arrival to retain the Czech Republic's attractiveness not only in terms of low operating and labour costs but also in terms of introducing activities with a higher added value.
The new legislation is also seen as one step towards satisfying the need to strengthen the EU's competitiveness, which the Czech Republic assumed as part of the so-called Lisbon strategy.

Czech/SlovakiaCzech RepublicSlovakia

21.02.2009

Prague – At a meeting with Czech stakeholders in Prague in December, EuropaBio expressed its appreciation that the Czech Republic is one of the ‘pro-biotech’ EU member states. In January when the Czech Republic took over the...

Czech/SlovakiaCzech RepublicSlovakia

11.11.2008

Prague/Tokyo – Tokyo-based Otsuka Pharmaceutical has established its first research, development and manufacturing facility in Eastern Europe. By the end of August, the diversified company had completed the acquisition of Czech...

Czech/SlovakiaCzech RepublicSlovakia

22.08.2008

Prague – Czech scientists have appealed to the European Council not to to politicise the approval process for biotech crops. “Although the EU has the strictest rules on GM plants in the world, politicians in Brussels prefer to...

Czech/SlovakiaCzech RepublicSlovakia

16.07.2008

Brno – Czech biotechnologists and EU industry experts have worked out an action plan to improve the development of industrial biotechnology in the Czech Republic. The recommendations are based on three SWOT analyses (R&D,...

Czech/SlovakiaCzech RepublicSlovakia

20.05.2008

Bratisava – German Lanxess, specialist for the development, manufacture and distribution of specialty chemicals and intermediates, has opened a new sales company for Central/Eastern Europe in Bratislava. This is its 3rd...

Czech/SlovakiaCzech RepublicSlovakia

20.05.2008

Prague – Gate2biotech has released a report on what’s going on in biotechnology in the Czech Republic. Windows-users can download a free electronic copy of the company registry and academic landscape or order a hardcopy at:...

Czech/SlovakiaCzech RepublicSlovakia

19.03.2008

Prague – The worldwide clinical research organisation Icon plc (Dublin, Ireland) has further expanded its activities in Eastern Europe. The CRO opened offices in Prague (Czech Republic), Kiev (Ukraine), and Bucharest (Romania),...

Czech/SlovakiaCzech RepublicSlovakia

22.11.2007

Prague – The Czech Republic has increased its R&D expenditures significantly in the last year. At a1.88 billion, R&D investments rose by 18% compared to 2005, the second largest increase world-wide. Those expenditures achieved...

Czech/SlovakiaCzech RepublicSlovakia

22.11.2007

Kourim/Basel – Lonza Biotec s.r.o. (Kourim, Czech Republic), a specialist for microbial fermentation and manufacturing services, has completed the extension of its production plant in Kourim designed for the cGMP-compliant...

Czech/SlovakiaCzech RepublicSlovakia

22.11.2007

Prague – Prague Clinical Services s.r.o. will conduct the pivotal phase III trials in Europe for Gia­conda Ltd.’s (Sydney, Australia) lead product Myoconda®, an anti­biotic combination therapy for the treatment of MAP infection...

Displaying results 21 to 30 out of 70

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-czech-slovakia/browse/2/article/new-instrument-gives-tax-breaks-for-rd-in-the-czech-republic.html

Print Magazine

Product of the week

Products

Events

All Events

Stock list

All quotes

TOP

  • CO.DON2.65 EUR6.00%
  • FORMYCON10.90 EUR4.51%
  • CYTOS0.29 CHF3.57%

FLOP

  • BIOTEST79.48 EUR-2.68%
  • ADDEX2.99 CHF-1.97%
  • EVOTEC3.23 EUR-1.22%

TOP

  • CYTOS0.29 CHF81.2%
  • EPIGENOMICS5.16 EUR46.2%
  • FORMYCON10.90 EUR38.9%

FLOP

  • THERAMETRICS0.07 CHF-12.5%
  • BIOFRONTERA2.59 EUR-10.7%
  • ADDEX2.99 CHF-9.4%

TOP

  • SANTHERA92.95 CHF2525.7%
  • CO.DON2.65 EUR154.8%
  • BB BIOTECH183.40 EUR63.9%

FLOP

  • CYTOS0.29 CHF-91.3%
  • 4SC0.90 EUR-48.0%
  • THERAMETRICS0.07 CHF-46.2%

No liability assumed, Date: 25.11.2014

Current issue

All issues